Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Standard Biotools (LAB) Equity Average (2016 - 2025)

Historic Equity Average for Standard Biotools (LAB) over the last 15 years, with Q3 2025 value amounting to $412.1 million.

  • Standard Biotools' Equity Average fell 1754.71% to $412.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $412.1 million, marking a year-over-year decrease of 1754.71%. This contributed to the annual value of $161.8 million for FY2024, which is 24102.21% up from last year.
  • Standard Biotools' Equity Average amounted to $412.1 million in Q3 2025, which was down 1754.71% from $439.6 million recorded in Q2 2025.
  • Standard Biotools' Equity Average's 5-year high stood at $543.8 million during Q2 2024, with a 5-year trough of -$139.9 million in Q4 2023.
  • Moreover, its 5-year median value for Equity Average was $104.4 million (2021), whereas its average is $156.5 million.
  • Its Equity Average has fluctuated over the past 5 years, first tumbled by 127240.08% in 2023, then soared by 61656.55% in 2024.
  • Standard Biotools' Equity Average (Quarter) stood at $97.0 million in 2021, then tumbled by 174.36% to -$72.1 million in 2022, then plummeted by 94.0% to -$139.9 million in 2023, then soared by 443.51% to $480.5 million in 2024, then fell by 14.24% to $412.1 million in 2025.
  • Its last three reported values are $412.1 million in Q3 2025, $439.6 million for Q2 2025, and $463.2 million during Q1 2025.